Eli Lilly's next Phase III trial is assessing whether lepodisiran can not only reduce levels of lipoprotein(a) but also ...

The firm's artificial intelligence-based biomarker tools including Lunit Scope IO and Lunit Scope Universal IHC will be available across trials at the Center for Cancer Research.

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

The antithrombin assay will support dosing Qfitlia, the sixth Alnylam-discovered RNAi medicine to receive FDA approval.

Researchers at ACC suggested stratifying by age and TTR variant, plus cascade testing, could help identify those likely to ...

NEW YORK – Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of a subcutaneous formulation of its PD-1 ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Researchers at the American College of Cardiology's annual meeting used proteomic approaches to uncover dysregulated signaling pathways in the disease.

NEW YORK – Some patients with KRAS G12C-mutant and PD-L1-high advanced non-small cell lung cancer lived for more than two years without their cancer progressing on first-line combination treatment ...

NEW YORK – The US Food and Drug Administration on Friday expanded the indication for Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use prior to chemotherapy in ...